scholarly journals Sporadic late onset nemaline myopathy with monoclonal gammopathy of undetermined significance: two cases with long term stability

Author(s):  
André Truffert ◽  
Ruxandra Iancu Ferfoglia ◽  
Johannes Alexander Lobrinus ◽  
Kaveh Samii ◽  
André Kohler

Monoclonal gammopathy of undetermined significance (MGUS) associated to sporadic late onset nemaline myopathy (SLONM) is a rare and severely disabling condition of quickly progressive limb girdle acquired myopathy. It is believed by some authors to be due to myotoxicity of light chain deposits. Two female patients were diagnosed with MGUS associated SLONM. In the first case, diagnosis was delayed by 6 years thus giving time for a severe generalized myopathy and cardiomyopathy to develop. A single anti-myeloma chemotherapy with lenalidomide markedly improved and stabilized the patient’s condition despite respiratory and cardiac insufficiency. In our second patient the condition was identified one year after onset of the first symptom and markedly improved after autologous bone marrow transplantation and lenalidomide. Clinicians should be aware of monoclonal gammopathy associated sporadic late onset nemaline myopathy as this acquired muscle disorder, although extremely rare, may be reversed by adequate management.

2020 ◽  
Vol 30 (3) ◽  
Author(s):  
André Truffert ◽  
Ruxandra Iancu Ferfoglia ◽  
Johannes Alexander Lobrinus ◽  
Kaveh Samii ◽  
André Kohler

Monoclonal gammopathy of undetermined significance (MGUS) associated to sporadic late onset nemaline myopathy (SLONM) is a rare and severely disabling condition of quickly progressive limb girdle acquired myopathy. It is believed by some authors to be due to myotoxicity of light chain deposits. Two female patients were diagnosed with MGUS associated SLONM. In the first case, diagnosis was delayed by 6 years thus giving time for a severe generalized myopathy and cardiomyopathy to develop. A single anti-myeloma chemotherapy with lenalidomide markedly improved and stabilized the patient’s condition despite respiratory and cardiac insufficiency. In our second patient the condition was identified one year after onset of the first symptom and markedly improved after autologous bone marrow transplantation and lenalidomide. Clinicians should be aware of monoclonal gammopathy associated sporadic late onset nemaline myopathy as this acquired muscle disorder, although extremely rare, may be reversed by adequate management.


2021 ◽  
Vol 31 (1) ◽  
pp. 29-34
Author(s):  
Ali Asghar Okhovat ◽  
Yalda Nilipour ◽  
Reza Boostani ◽  
Fahimeh Vahabizad ◽  
Safa Najmi ◽  
...  

Author(s):  
Tania Maia ◽  
Rui Bergantim ◽  
Henrique Costa ◽  
Jorge Pinheiro ◽  
Fernanda Trigo

Monoclonal gammopathy of undetermined significance (MGUS) may be associated with pathologies with severe neuromuscular manifestations such as sporadic late-onset nemaline myopathy (SLONM). We describe a difficult to diagnose case of SLNOM with marked clinical improvement after achieving gammopathy complete hematologic response.


1998 ◽  
Vol 21 (1) ◽  
pp. 40-46
Author(s):  
G. Mazzi ◽  
A. Raineri ◽  
M. Zucco ◽  
P. Passadore ◽  
A. Pomes ◽  
...  

We investigated 19 patients affected by chronic peripheral neurological disorders treated with therapeutic plasma exchange (TPE) to verify the efficacy of the therapeutic protocol used in these diseases. Every patient was clinically considered after 5 TPE. Those who showed an improvement started chemotherapy and continued TPE at the rate of 2 procedures/week for 2 weeks, then 1 procedure/week for 1 month and finally 1 procedure every 2 weeks for 2 months. Intravenous immunoglobulins (IVIg) were infused at the end of apheretic treatment in one of the patients affected by neurological disorders due to monoclonal gammopathy undetermined significance. HCV-positive patients with cryoglobulins were treated with α-interferon (α-IFN) for 6 months before TPE. Eleven patients (58%) had a symptomatic improvement, 2 (1.5%) stopped TPE treatment owing to side effects and 6 (31.5%) did not respond to apheretic therapy. In order to improve the advantages of TPE we suggest using IVIg at the end of apheretic therapy, while in HCV-positive patients, at least one year of α-IFN therapy is required before initiating TPE.


2009 ◽  
Vol 41 (2) ◽  
pp. 286-287 ◽  
Author(s):  
Jan Novy ◽  
Anne Rosselet ◽  
Olivier Spertini ◽  
Johannes Alexander Lobrinus ◽  
Thomas Pabst ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document